Photo of Craig Okada, MD

Craig Okada MD

Dr. Okada specializes in the care of patients with lymphoma. He joined OHSU in 2004 and has a particular interest the treatment of cutaneous lymphoma and immunotherapy. With over 30 different types of lymphoma, focusing his practice in lymphoma allows Dr. Okada to appreciate the subtle difference between the various kinds of lymphoma. This kind of expertise helps in choosing the best treatment for each patient. 

Dr. Okada is part of the OHSU multidisciplinary lymphoma group, which allows for coordinated care from radiation oncology, oncology and bone marrow transplant. He conducts several clinical trials in lymphoma, making promising new treat available for patients with this disease.

Read more


  • Ph.D., Stanford University, Palo Alto California 0 1990
  • M.D., Stanford University, Palo Alto California 0 1990
  • Residency:

    • Stanford University, 1992
  • Fellowship:

    • Hematology, Stanford University, 1993
  • Certifications:

    • American Board of Internal Medicine (hematology), 1996 (recertified 2007)

Memberships and associations

  • American Society of Hematology


  • "Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia." Leukemia and Lymphoma  In: , 19.12.2017, p. 1-3.
  • "Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma." Leukemia and Lymphoma In: , 04.12.2017, p. 1-6.
  • "Diffuse large B-cell lymphoma in adults aged 75 years and older : A single institution analysis of cause-specific survival and prognostic factors." Therapeutic Advances in Hematology  In: , Vol. 4, No. 6, 2013, p. 349-353.
  • "Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma." Leukemia and Lymphoma In: , Vol. 52, No. 8, 08.2011, p. 1488-1494.
  • "A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma." Haematologica Meeting Reports In: , Vol. 2, No. 5, 2008, p. 44-45.
  • "Gene expression and angiotropism in primary CNS lymphoma." Blood  In: , Vol. 107, No. 9, 01.05.2006, p. 3716-3723.
  • "Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma." Cancer Immunology, Immunotherapy In: , Vol. 55, No. 4, 04.2006, p. 420-432.
  • "Galloping ophthalmoplegia and numb chin in Burkitt lymphoma." Journal of Neuro-Ophthalmology In: , Vol. 24, No. 2, 06.2004, p. 130-134.
  • "TCR Vaccines against a Murine T Cell Lymphoma : A Primary Role for Antibodies of the IgG2c Class in Tumor Protection." Journal of Immunology  In: , Vol. 172, No. 2, 15.01.2004, p. 929-936.
  • "Erratum : Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma (Journal of Immunology (2002) 169 (5225-5235))." Journal of Immunology In: , Vol. 170, No. 10, 15.05.2003, p. 5333.
  • "Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma." Journal of Immunology In: , Vol. 169, No. 9, 01.11.2002, p. 5227-5235.
  • "Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma : Clinical and immune responses in 35 patients." Blood  In: , Vol. 99, No. 5, 01.03.2002, p. 1517-1526.
  • "T cell antigen receptor vaccines for active therapy of T cell malignancies." Annals of the New York Academy of Sciences  In: , Vol. 941, 2001, p. 97-105.
  • "Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas." Blood  In: , Vol. 95, No. 5, 01.03.2000, p. 1797-1803.
  • "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study." Blood  In: , Vol. 93, No. 7, 01.04.1999, p. 2411-2419.
  • "TCR vaccines against T cell lymphoma : QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response." Journal of Immunology  In: , Vol. 162, No. 4, 15.02.1999, p. 2251-2258.
  • "T cell antigen receptor vaccines for active immunotherapy of T cell malignancies." FASEB Journal  In: , Vol. 12, No. 5, 20.03.1998.
  • "TCR Vaccines for Active Immunotherapy of T Cell Malignancies." Journal of Immunology  In: , Vol. 159, No. 11, 01.12.1997, p. 5516-5527.
  • "Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma." Biology of Blood and Marrow Transplantation  In: , Vol. 3, No. 3, 08.1997, p. 157-163.
  • "Characterization of a rat monoclonal antibody specific for a determinant encoded by the Vβ7 gene segment : Depletion of Vβ7+ T cells in mice with Mls-1 a haplotype." Journal of Immunology In: , Vol. 144, No. 9, 01.05.1990, p. 3473-3477.
  • "Relative V(β) transcript levels in thymus and peripheral lymphoid tissues from various mouse strains. Inverse correlation of I-E and Mls expression with relative abundance of several V(β) transcripts in peripheral lymphoid tissues." Journal of Experimental Medicine In: , Vol. 169, No. 5, 1989, p. 1703-1719.
  • "A high proportion of T lymphocytes that infiltrate H-2-incompatible heart allografts in vivo express genes encoding cytotoxic cell-specific serine proteases, but do not express the mel-14-defined lymph node homing receptor." Journal of Experimental Medicine In: , Vol. 167, No. 3, 1988, p. 1124-1136.
  • "Expression of two serine esterase genes during an allograft rejection in the mouse." Transplantation Proceedings In: , Vol. 20, No. 2, 1988, p. 251-253.
  • "Early events in T-cell maturation." Annual Review of Immunology In: , Vol. 5, 1987, p. 325-365.
  • "The murine T-cell receptor uses a limited repertoire of expressed V gene segments." Nature  In: , Vol. 316, No. 6028, 1985, p. 517-523.
  • "Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles." Cell  In: , Vol. 29, No. 1, 1982, p. 33-41.
  • "A rapid procedure for assaying nicotinamide phosphoribosyltransferase." Analytical Biochemistry In: , Vol. 107, No. 1, 1980, p. 199-205.

Additional information

Edit profile